The effect of glucomannan supplementation on lipid profile in adults: a GRADE-assessed systematic review and meta-analysis.

2024-10-09
BMC cardiovascular disorders 24(1)
- Vali Musazadeh
- Rogheye Yaraee Rostami
- Amir Hossein Moridpour
- Zahra Bokaii Hosseini
- Omid Nikpayam
- Maryam Falahatzadeh
- Amir Hossein Faghfouri

PubMed: 39385065
DOI: 10.1186/s12872-024-04223-0

Study Design

Type: Meta-Analysis
Population: adults
Methods: Comprehensive search across Scopus, PubMed, Embase, and Web of Science from inception to June 2024 to identify RCTs assessing glucomannan supplementation on lipid profile; data extracted and analyzed using random effects model

Background

Glucomannan has been studied for various health benefits, but its effects on lipid profile in adults are not well understood. This meta-analysis aims to evaluate the impact of glucomannan supplementation on serum/plasma levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), Apo B1, Apo A1, APO-B/ A1 ratio, and LDL-C/ HDL-C in adults.

Methods

A comprehensive search was conducted across Scopus, PubMed, Embase, and Web of Science from inception to June 2024 to identify randomized controlled trials (RCTs) assessing glucomannan supplementation on lipid profile in adults. Data were extracted and analyzed using random effects model to determine the standardized mean differences (SMDs) and 95% confidence intervals (CIs) for each biomarker.

Results

Glucomannan supplementation significantly decreased TC (SMD: -3.299; 95% CI: -4.955, -1.664, P < 0.001; I ² = 95.41%, P-heterogeneity < 0.001), LDL-C (SMD: -2.993; 95% CI: -4.958, -1.028; P = 0.006; I ² = 95.49%, P-heterogeneity < 0.001), and Apo B1 (SMD: -2.2; 95% CI: -3.58, -0.82; P = 0.01). However, glucomannan did not alter the levels of TG (SMD: -0.119; 95% CI: -1.076, 0.837, P = 0.789; I ² = 91.63%, P-heterogeneity < 0.001), Apo A1 (SMD: -0.48; 95% CI: -6.27, 5.32; P = 0.76), APO-B/ A1 ratio (SMD: -1.15; 95% CI: -2.91, 0.61; P = 0.11), and LDL-C/ HDL-C ratio (SMD: -2.2; 95% CI: -7.28, 2.87; P = 0.2).

Conclusions

Glucomannan supplementation has a beneficial effect on the level of TC and LDL-C.

Research Insights

Konjac→Reduced APO-B/A1 Ratio
glucomannan did not alter the levels of APO-B/ A1 ratio (SMD: -1.15; 95% CI: -2.91, 0.61; P = 0.11)
Effect
Neutral
Effect size
Small
Konjac→Reduced Apo B to Apo A1 Ratio
glucomannan did not alter the levels of ... APO-B/ A1 ratio (SMD: -1.15; 95% CI: -2.91, 0.61; P = 0.11)
Effect
Neutral
Effect size
Small
Konjac→Reduced Apolipoprotein B Level
Glucomannan supplementation significantly decreased Apo B1 (SMD: -2.2; 95% CI: -3.58, -0.82; P = 0.01)
Effect
Beneficial
Effect size
Large
Konjac→Reduced Apolipoprotein B Levels
glucomannan did not alter the levels of Apo A1 (SMD: -0.48; 95% CI: -6.27, 5.32; P = 0.76)
Effect
Neutral
Effect size
Small
Konjac→Reduced Blood Cholesterol
Glucomannan supplementation significantly decreased TC (SMD: -3.299; 95% CI: -4.955, -1.664, P < 0.001; I2 = 95.41%, P-heterogeneity < 0.001)
Effect
Beneficial
Effect size
Large
Konjac→Reduced LDL Cholesterol
Glucomannan supplementation significantly decreased LDL-C (SMD: -2.993; 95% CI: -4.958, -1.028; P = 0.006)
Effect
Beneficial
Effect size
Large
Konjac→Reduced LDL-C/HDL-C Ratio
glucomannan did not alter the levels of LDL-C/ HDL-C ratio (SMD: -2.2; 95% CI: -7.28, 2.87; P = 0.2)
Effect
Neutral
Effect size
Small
Konjac→Reduced LDL-to-HDL Cholesterol Ratio
glucomannan did not alter the levels of ... LDL-C/ HDL-C ratio (SMD: -2.2; 95% CI: -7.28, 2.87; P = 0.2)
Effect
Neutral
Effect size
Small
Konjac→Reduced Low-Density Lipoprotein Level
Glucomannan supplementation significantly decreased ... LDL-C (SMD: -2.993; 95% CI: -4.958, -1.028; P = 0.006; I2 = 95.49%, P-heterogeneity < 0.001)
Effect
Beneficial
Effect size
Large
Konjac→Reduced Triglyceride Levels
glucomannan did not alter the levels of TG (SMD: -0.119; 95% CI: -1.076, 0.837, P = 0.789)
Effect
Neutral
Effect size
Small